2. Signaling Pathways
  3. Epigenetics
  4. Epigenetic Reader Domain
  5. BD1 Isoform

BD1

BD1 is the first bromodomain of BET proteins, whose two tandem bromodomains enable chromatin binding to facilitate transcription[1]. Mechanistically, BET proteins recognize acetylated histones and recruit transcription factors and P-TEFb to chromatin, promoting RNA polymerase II phosphorylation and transcription initiation and elongation[2]. In cancer and immunoinflammation models, steady-state gene expression primarily requires BD1, whereas inflammatory stimulus-induced rapid gene expression requires both BD1 and BD2[1]. Compared with BD2, BD1 therefore provides a stronger experimental handle for studying transcriptional maintenance and cancer-model responses, because BD1 inhibitors phenocopied pan-BET inhibitors in cancer models[1]. For research applications, JQ1 and I-BET established acetyl-lysine/bromodomain inhibition as chemical-probe strategies, while GSK789 and Olinone support domain-selective interrogation of BET-BD1 biology[3][4][5][6]. - BD1 supports steady-state transcription and chromatin engagement across BET protein research models. - BD1-selective inhibitors help separate cancer-model effects from BD2-linked inflammatory responses.

BD1 Related Products (9):

Cat. No. Product Name Effect Purity
  • HY-114416
    GS-626510
    		Inhibitor 99.46%
    GS-626510 is a potent, and orally active BET family bromodomains inhibitor, with Kd values of 0.59-3.2 nM for BRD2/3/4, with IC50 values of 83 nM and 78 nM foe BD1 and BD2, respectively.
  • HY-178041
    BRD4-BD1/2-IN-3
    		Inhibitor 99.52%
    BRD4-BD1/2-IN-3 (Compound B6) is a selective BRD4 BD2 inhibitor with an IC50 of 0.41  nM for BRD4 BD2 over BRD4 BD1. BRD4-BD1/2-IN-3 significantly inhibits the LPS (HY-D1056)-induced expression of IL-6. BRD4-BD1/2-IN-3 shows anti-inflammatory activities by modulating the TNF and NF-κB signaling pathway. BRD4-BD1/2-IN-3 can be used for inflammatory diseases research.
  • HY-160634
    BRD4 Inhibitor-31
    		Inhibitor
    BRD4 Inhibitor-31 (Example 136) is a BRD4 inhibitor (Kis: 0.234 μM and 0.295 μM for BRD4 BD1 and BRD4 BD2 respectively). BRD4 Inhibitor-31 can be used for research of inflammatory diseases, cancer, and AIDS.
  • HY-146741
    SDR-04
    		Inhibitor
    SDR-04 is a BET inhibitor and exhibits strong BRD4-BD1 affinity and inhibition activity. SDR-04 potently suppresses MV4;11 cancer cell line proliferation.
  • HY-162622
    BET-IN-26
    		Inhibitor
    BET-IN-26 (compound 13a) is a potent, selective and orally active BD1 inhibitor with IC50 values of 0.0055, 9.0 µM for BD1, BD2, respectively. BET-IN-26 decreases LPS (HY-D1056) induced serum levels of IL-6 and MCP-1.
  • HY-183922
    SRX3212
    		Inhibitor
    SRX3212 is a potent PI3Kα/BRD4 inhibitor with human IC50 values of 22 nM, 3.7 nM, and 32 nM for PI3Kα, BRD4BD1, and BRD4BD2, respectively. SRX3212 inhibits PI3K kinase activity and blocks acetyllysine binding function of BRD4BD1 and BRD4BD2. SRX3212 can be used for the research of mantle cell lymphoma, colon carcinoma, neuroblastoma, prostate cancer[1].
  • HY-173237
    CDK4/6/BRD4-IN-1
    		Inhibitor
    CDK4/6/BRD4-IN-1 (B15) is an inhibitor of CDK4, CDK6 and BRD4, with IC50 values of 220 nM, 146 nM, 106 nM and 85 nM for BRD4-BD2, BRD4-BD1, CDK6 and CDK4, respectively. CDK4/6/BRD4-IN-1 (B15) can be used in the study of NSCLC (Non-Small Cell Lung Cancer). CDK4/6/BRD4-IN-1 (B15) induces cell cycle arrest and apoptosis.
  • HY-155078
    BRD4 Inhibitor-27
    		Inhibitor
    BRD4 Inhibitor-27 (compound 6) is a BRD4 inhibitor with IC50 of 9.6 and 11.3 μM for BRD4 BD1 and BRD4 BD2, respectively. BRD4 Inhibitor-27 has the potential to study cancer.
  • HY-146739
    BRD4 Inhibitor-19
    		Inhibitor
    BRD4 Inhibitor-19 is a BET inhibitor with an IC50 of 55 nM for BRD4-BD1. BRD4 Inhibitor-19 can be used for multiple myeloma research.